FMR LLC lowered its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 95.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 97,358 shares of the biopharmaceutical company's stock after selling 2,269,618 shares during the quarter. FMR LLC owned about 0.06% of ACADIA Pharmaceuticals worth $1,497,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Park Place Capital Corp bought a new position in shares of ACADIA Pharmaceuticals in the third quarter valued at approximately $25,000. Values First Advisors Inc. bought a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $27,000. Quest Partners LLC raised its holdings in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 1,047 shares during the last quarter. Stonepine Capital Management LLC bought a new position in shares of ACADIA Pharmaceuticals during the second quarter valued at about $81,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in ACADIA Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,066 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Raymond James reiterated a "market perform" rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Finally, StockNews.com downgraded shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 14th. Six equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.60.
View Our Latest Research Report on ACAD
ACADIA Pharmaceuticals Price Performance
Shares of ACAD traded up $0.08 during midday trading on Monday, hitting $17.34. 1,539,216 shares of the company traded hands, compared to its average volume of 1,672,259. ACADIA Pharmaceuticals Inc. has a one year low of $14.15 and a one year high of $32.59. The firm has a market cap of $2.89 billion, a P/E ratio of 22.23 and a beta of 0.40. The stock has a 50-day moving average of $16.00 and a 200-day moving average of $16.17.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.14 by $0.06. The firm had revenue of $250.40 million during the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business's quarterly revenue was up 18.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.40) EPS. Sell-side analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.73 EPS for the current fiscal year.
Insider Buying and Selling at ACADIA Pharmaceuticals
In related news, insider James Kihara sold 4,073 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the transaction, the insider now owns 19,863 shares of the company's stock, valued at $333,897.03. This represents a 17.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark C. Schneyer sold 10,259 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $172,453.79. Following the sale, the chief financial officer now directly owns 53,302 shares of the company's stock, valued at approximately $896,006.62. This trade represents a 16.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,661 shares of company stock valued at $414,551 in the last 90 days. Corporate insiders own 28.30% of the company's stock.
ACADIA Pharmaceuticals Company Profile
(
Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Read More
Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.